ERBB2 and triple-negative breast carcinoma: Further studies in larger and broader patient populations should be conducted to gather additional psychometric evidence to confirm the scale structure and meaningful change thresholds of the NFBSI-16 in related populations, such as HR+, HER2− and visceral metastases [42], HER2 positive or triple negative breast cancer.